Loading
VNX-202 is an experimental in vivo gene therapy: AAV vector encoding a bispecific T-cell engager from Vironexis Biotherapeutics, in phase 1 trials for HER2-expressing solid tumours.
VNX-202 (AAV.CD3/HER2) is an in vivo gene therapy: AAV vector encoding a bispecific T-cell engager from Vironexis Biotherapeutics. A single intravenous dose of an adeno-associated virus vector encoding a CD3 x HER2 bispecific T-cell engager. Its furthest stage is phase 1, for HER2-expressing solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT07192432 recruiting. Whether it works in people has not been established unless a trial below reports it.
1.One arm of VNX-202 binds HER2 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VNX-202" OR ABSTRACT:"VNX-202" OR TITLE:"AAV.CD3/HER2" OR ABSTRACT:"AAV.CD3/HER2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VNX-202, not a curated reading list.
Shares Vironexis Biotherapeutics, CD3 and the tag pipeline.
Shares Vironexis Biotherapeutics and the tag pipeline.
Shares CD3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vironexis Biotherapeutics and the tag pipeline.
Shares CD3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CD3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/